Novartis (NVS) Stock Forecast & Price Target

Compare

3,849 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVS Analyst Ratings

Hold

1 Buy

2 Hold

1 Sell

Based on 4 analysts giving stock ratings to

Novartis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVS Stock 12 Month Forecast

Average Price Target

$131.67

▼(-3.23% Downside)

Based on 4 Wall Street analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $131.67 with a high forecast of $143.00 and a low forecast of $112.00. The average price target represents a -3.23% change from the last price of $136.06.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"93":"$93","144":"$144","105.75":"$105.8","118.5":"$118.5","131.25":"$131.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":131.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$131.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[93,105.75,118.5,131.25,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.97,130.04923076923077,131.12846153846155,132.2076923076923,133.28692307692307,134.36615384615385,135.44538461538463,136.52461538461537,137.60384615384615,138.68307692307692,139.7623076923077,140.84153846153845,141.92076923076922,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.97,129.1776923076923,129.38538461538462,129.59307692307692,129.80076923076922,130.00846153846155,130.21615384615384,130.42384615384614,130.63153846153844,130.83923076923077,131.04692307692306,131.25461538461536,131.4623076923077,{"y":131.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,128.97,127.66461538461539,126.35923076923076,125.05384615384615,123.74846153846154,122.44307692307692,121.1376923076923,119.8323076923077,118.52692307692308,117.22153846153846,115.91615384615385,114.61076923076922,113.30538461538461,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":101.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.45,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.84,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.72,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.79,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.97,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$143.00

Average Price Target$131.67

Lowest Price Target$112.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Rajesh Kumar

HSBC

$106→$112

Sell

-17.68%

Downside

Reiterated

12/10/25

Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC

Thibault Boutherin

Morgan Stanley

$136→$143

Buy

5.10%

Upside

Upgraded

12/03/25

Novartis price target raised to $143 from $136 at Morgan StanleyNovartis price target raised to $143 from $136 at Morgan Stanley

Richard Vosser

J.P. Morgan

―

Hold

―

Reiterated

11/20/25

J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)

Steve Scala

TD Cowen

$125→$140

Hold

2.90%

Upside

Reiterated

11/10/25

James Quigley

Goldman Sachs

$119→$118

Sell

-13.27%

Downside

Downgraded

09/12/25

Novartis (NVS) was downgraded to a Sell Rating at Goldman SachsGoldman Sachs analyst James Quigley downgraded Novartis (NYSE: NVS) from Neutral to Sell with a price target of $118.00 (from $119.00).

Kerry Holford

Berenberg Bank

$108

Hold

-20.62%

Downside

Reiterated

07/22/25

Novartis (NVS) Gets a Hold from Berenberg Bank

Sachin Jain

Bank of America Securities

$139.52

Hold

2.55%

Upside

Reiterated

06/02/25

Novan (NOVN) Gets a Hold from Bank of America Securities

Peter Verdult

Exane BNP Paribas

$116

Buy

-14.74%

Downside

Initiated

04/15/25

Novartis initiated with an Outperform at BNP Paribas ExaneNovartis initiated with an Outperform at BNP Paribas Exane

Unknown Analyst

Edgewater Research

Not Ranked

Edgewater Research

$116

Buy

-14.74%

Downside

Initiated

04/15/25

Edgewater Research starts Novartis (NVS) at OutperformEdgewater Research initiates coverage on Novartis (NYSE: NVS) with a Outperform rating and a price target of $116.00.

Unknown Analyst

Argus Research

Not Ranked

Argus Research

―

Hold

―

Reiterated

04/04/25

we are raising our 2025 adjusted EPS estimate to $8.45 from $8.10

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Rajesh Kumar

HSBC

$106→$112

Sell

-17.68%

Downside

Reiterated

12/10/25

Novartis price target raised to $112 from $106 at HSBCNovartis price target raised to $112 from $106 at HSBC

Thibault Boutherin

Morgan Stanley

$136→$143

Buy

5.10%

Upside

Upgraded

12/03/25

Novartis price target raised to $143 from $136 at Morgan StanleyNovartis price target raised to $143 from $136 at Morgan Stanley

Richard Vosser

J.P. Morgan

―

Hold

―

Reiterated

11/20/25

J.P. Morgan Sticks to Its Hold Rating for Novartis (NVS)

Steve Scala

TD Cowen

$125→$140

Hold

2.90%

Upside

Reiterated

11/10/25

James Quigley

Goldman Sachs

$119→$118

Sell

-13.27%

Downside

Downgraded

09/12/25

Novartis (NVS) was downgraded to a Sell Rating at Goldman SachsGoldman Sachs analyst James Quigley downgraded Novartis (NYSE: NVS) from Neutral to Sell with a price target of $118.00 (from $119.00).

Kerry Holford

Berenberg Bank

$108

Hold

-20.62%

Downside

Reiterated

07/22/25

Novartis (NVS) Gets a Hold from Berenberg Bank

Sachin Jain

Bank of America Securities

$139.52

Hold

2.55%

Upside

Reiterated

06/02/25

Novan (NOVN) Gets a Hold from Bank of America Securities

Peter Verdult

Exane BNP Paribas

$116

Buy

-14.74%

Downside

Initiated

04/15/25

Novartis initiated with an Outperform at BNP Paribas ExaneNovartis initiated with an Outperform at BNP Paribas Exane

Unknown Analyst

Edgewater Research

Not Ranked

Edgewater Research

$116

Buy

-14.74%

Downside

Initiated

04/15/25

Edgewater Research starts Novartis (NVS) at OutperformEdgewater Research initiates coverage on Novartis (NYSE: NVS) with a Outperform rating and a price target of $116.00.

Unknown Analyst

Argus Research

Not Ranked

Argus Research

―

Hold

―

Reiterated

04/04/25

we are raising our 2025 adjusted EPS estimate to $8.45 from $8.10

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novartis

1 Month

xxx

Success Rate

9/11 ratings generated profit

Average Return

+2.96%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 81.82% of your transactions generating a profit, with an average return of +2.96% per trade.

3 Months

xxx

Success Rate

11/11 ratings generated profit

Average Return

+7.15%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +7.15% per trade.

1 Year

Veda PharmyneTR | OpenAI - 4o

Success Rate

11/11 ratings generated profit

Average Return

+20.64%

reiterated a buy rating last month

Copying Veda Pharmyne's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +20.64% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+21.58%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +21.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVS has received 4 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. NVS average Analyst price target in the past 3 months is 131.67.

Each month's total comprises the sum of three months' worth of ratings.

NVS Financial Forecast

NVS Earnings Forecast

Next quarter’s earnings estimate for NVS is $1.97 with a range of $1.91 to $2.10. The previous quarter’s EPS was $2.25. NVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NVS has Performed in-line its overall industry.

NVS Sales Forecast

Next quarter’s sales forecast for NVS is $13.80B with a range of $13.60B to $14.46B. The previous quarter’s sales results were $13.88B. NVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NVS has Performed in-line its overall industry.

NVS Stock Forecast FAQ

What is NVS’s average 12-month price target, according to analysts?

Based on analyst ratings, Novartis Ag’s 12-month average price target is 131.67.

What is NVS’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for NVS, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NVS a Buy, Sell or Hold?

Novartis Ag has a consensus rating of Hold which is based on 1 buy ratings, 2 hold ratings and 1 sell ratings.

What is Novartis Ag’s price target?

The average price target for Novartis Ag is 131.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $143.00 ,the lowest forecast is $112.00. The average price target represents -3.23% Decrease from the current price of $136.06.

What do analysts say about Novartis Ag?

Novartis Ag’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of NVS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Novartis (NVS) Stock Forecast & Price Target

NVS Analyst Ratings

NVS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novartis

NVS Analyst Recommendation Trends

NVS Financial Forecast

NVS Earnings Forecast

NVS Sales Forecast

NVS Stock Forecast FAQ

Detailed List of Analyst Forecasts